《新股》雲知聲(09678.HK)公開發售獲91.66倍認購 一手中籤率10%
雲知聲(09678.HK)公佈招股結果,香港公開發售接獲91.66倍認購,一手(20股)中籤率10.01%,認購500股獲穩派一手。按回補機制,公開發售股份已增至62.44萬股,佔發售總數40%。國際發售錄得1.7倍認購。最終發售價205元,上限定價,集資淨額2.06億元。股份預期週一(30日)上市。
對話式AI產品及解決方案供應商雲知聲是次擬全球發售近156.1萬股,公開發售原佔10%。招股價介乎165-205元。基石投資者商湯(00020.HK)旗下SensePower、資產管理公司臻一及潤建股份(002929.SZ)合共認購9,550萬元股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.